Aspira Women's Health Inc. (AWH)
- Previous Close
3.5000 - Open
3.5100 - Bid --
- Ask --
- Day's Range
3.3900 - 3.5200 - 52 Week Range
2.3100 - 6.7500 - Volume
7,802 - Avg. Volume
26,153 - Market Cap (intraday)
41.846M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.25
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a second-generation biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins, and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
aspirawh.com64
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AWH
Performance Overview: AWH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AWH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AWH
Valuation Measures
Market Cap
41.85M
Enterprise Value
42.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.42
Price/Book (mrq)
--
Enterprise Value/Revenue
4.60
Enterprise Value/EBITDA
-2.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-182.32%
Return on Assets (ttm)
-99.70%
Return on Equity (ttm)
-723.45%
Revenue (ttm)
9.15M
Net Income Avi to Common (ttm)
-16.69M
Diluted EPS (ttm)
-1.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.72M